Amir Goldkorn MD
Genitourinary Oncology
Associate Professor, Medicine, USC School of Medicine
Join to View Full Profile
1441 Eastlake AveLos Angeles, CA 90089
Phone+1 323-865-3105
Fax+1 323-442-5953
Dr. Goldkorn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California, San FranciscoPost-Doctoral Fellowship, 2002 - 2007
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1998 - 2001
David Geffen School of Medicine at UCLAClass of 1998
Certifications & Licensure
CA State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Publications & Presentations
PubMed
- 5 citationsCirculating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu
JAMA Network Open. 2024-10-01 - 3 citationsCorrelative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder C...Elizabeth R Plimack, Catherine Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu
European Urology. 2024-10-01 - Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III tria...Primo N Lara Jr, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn
Prostate Cancer and Prostatic Diseases. 2024-09-01
Press Mentions
Blood Test Predicts Outcomes in Newly Diagnosed Metastatic Prostate CancerOctober 9th, 2024- An Early Blood Test Can Predict Survival in Patients with Metastatic Prostate CancerOctober 7th, 2024
- Blood Test Can Help Predict Survival from Advanced Prostate CancerOctober 7th, 2024
- Join now to see all
Grant Support
- Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerUNIVERSITY OF SOUTHERN CALIFORNIA2021–2026
- Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerUNIVERSITY OF SOUTHERN CALIFORNIA2021–2026
- Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancerUNIVERSITY OF SOUTHERN CALIFORNIA2021–2026
- Targeting Cancer With Telomerase InterferenceNational Cancer Institute2007–2011
- Circulating Tumor Cell Capture &Analysis In A Multi-Center Prostate Cancer TrialNational Cancer Institute2009
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
